Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 1031-1038

  Warm, Mathias ^a,e   Kates, Ronald ^b   Mallmann, Peter ^a   Dick, Michèlle ^a   Nawroth, Frank ^c   Harbeck, Nadia ^b   Paepke, Stefan ^b   Thomas, Anke ^d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c ENDOKRINOLOGIKUM HAMBURG   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

^e Department of Senology ^*  (Germany)

Author keywords

Epirubicin paclitaxel; her2 neu; Pre operative therapy; Prediction of therapy response

Indexed keywords

BIOLOGICAL FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; POLYMERASE CHAIN REACTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; THREE DIMENSIONAL IMAGING; TREATMENT RESPONSE; ULTRASOUND; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 34247119374     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Fisher B, Brown A, Mamounas E, Wieand S, Fisher E, Robidoux A, Margolese R, Cruz A, Wickerham DL and Wolmark N: Effect of preoperative therapy for primary breast cancer (BC) on local-regional disease, disease-free survival (DFS) and survival (S): results from NSABP B-18. Proc Am Soc Clin Oncol 16: abstr 449, 1997.
2. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW and Dimitrov NV: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15(7): 2483-2493, 1997.
3. Untch M, Ditsch N, Bauerfeind I, Georges B, Kahlert S and Konecny G: Primäre Chemotherapie beim Mammakarzinom. In: Diagnostik und Therapie des Mammakarzinoms - State of the Art - (eds.). W. Zuckerschwerdt Verlag München, 2002.
4. Veronesi U, Bonadonna G, Zurrida Stefano, Galimberti V, Greco M, Brambilla C, Luini A, Rilke F, Raselli R, Merson M, Sacchini V and Agresti R: Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 222(5): 612-618, 1995.
5. Glueck S: The expanding role of epirubicin in the treatment of breast cancer. Cancer Control 9(2): 16-27, 2002.
6. Fumoleau P, Bonneterre J and Luporsi E: Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today? J Clin Oncol 21(6):1190-1191, 2003.
7. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 227: 665-667, 1979.
8. Dye RB, Fink SP and Williams Jr RC: Taxol-induced flexibility of microtubules and its reversal by MAP-2 and Tau. J Biol Chem 268: 6847-6850, 1993.
9. Bartsch V, Höffken K, Kreienberg R and Bamberg M: Das Taxol® - Buch, Thieme Verlag, Stuttgart - New York, 2000.
10. Ring AE and Ellis PA: Taxanes in the treatment of early breast cancer. Cancer Treat Rev 31: 618-627, 2005.
11. Nabholtz JM and Gligorov J: The role of taxanes in the treatment of breast cancer. Expert Opin Pharmacother 6: 1073-1094, 2005.
12. Martin M, Rodriguez-Lescure A, Ruiz A et al: Multicenter, randomized phase III study of adjuvant chemotherapy for node-positive breast cancer comparing 6 cycles of FEC versus 4 cycles of FEC followed by 8 weekly paclitaxel administrations: interim analysis of GEICAM 9906 trial. Breast Cancer Res Treat 94(suppl 1): abstr 39, 2005.
13. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A and Vogel C; Breast Cancer International Research Group 001 Investigators: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352(22): 2302-2313, 2005.
14. Early Breast Cancer Trialists' Collaborative Group: Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev 1: CD000487 (review), 2002.
15. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717, 2005.
16. Thomas A, Ohlinger R, Hauschild M, Mustea A, Blohmer JU and Kümmel S: Option and limit of surgery after preoperative chemotherapy in breast cancer. Anticancer Res 26(2C): 1677-1682, 2006.
17. Eifel P, Axelson JA and Costa J: National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer Nov 1-3, 2000. J Natl Cancer Inst 93: 979-989, 2001.
18. Schmidt-Matthiesen H, Bastert G and Wallwiener D: In: Gynäkologische Onkologie (eds.). Schattauer Verlag, S. pp: 128-131, 2002.
19. Sinn HP, Schmid H, Junkermann H et al: Histologische Regression des Mammakarzinoms nach primärer (neoadjuvanter) Chemotherapie. Geburtsh u Frauenh 54: 552-558, 1994.
20. Kimura M and Tominaga T: Outstanding problems with response evaluation criteria in solid tumors (RECIST) in breast cancer. Breast Cancer 9(2): 153-159, 2002.
21. Bonadonna G, Veronesi U and Brambilla C: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82: 1539-1545, 1990.
22. Anderson ED, Forrest AP and Hawkins RA: Primary systemic therapy for operable breast cancer. Br J Cancer 63: 561-566, 1991.
23. Jacquillat C, Weil M and Baillet F: Results of neoadjuvant chemotherpy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66: 119-129, 1990.
24. Smith IE, Jones AL and O'Brien ME: Primary medical (neoadjuvant) chemotherapy for operable breast cancer. Eur J Cancer 29A: 1796-1799, 1993.
25. Smith IE, Walsh G, Jones A and Prendiville J: High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13: 424-429, 1995.
26. Chollet P, Charrier S and Brain E: Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 33: 862-866, 1997.
27. Bilchert-Toft M, Smola MG, Cataliotti L and O'Higgins N: Principles and guidelines for surgeons - management of symptomatic breast cancer. European Society of Surgical Oncology. Eur J Surg Oncol 23: 101-109, 1997.
28. Fisher B, Bryant J, Wolmark N, Marmounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB, Hoehn JL, Lees AW, Dimitrov NV and Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998.
29. Bonadonna G, Valgussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M and Zambetti M: Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93-100, 1998.
30. Hortobagyi G and Budzar AU: Locally advanced breast cancer: a review including the M.D. Anderson experience. In: High Risk Breast Cancer. Ragaz J, Ariel I (eds.). Springer Verlag, Berlin, pp: 382-415, 1991.
31. von Minckwitz G: Taxane in der primären systemischen Therapie des Mammakarzinoms. Onkologie 26(7): 21-25, 2003.
32. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T and Senn HJ: International Consensus Panel on the primary systemic treatment of breast cancer-meeting highlights and recommendations. J Clin Oncol 21: 2600-2608, 2003.
33. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL and Cronin WM: Reanalysis and results after 12 years of follow-up in a randomised clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 345: 1378-1387, 2001.
34. Untch M, Konecny G, Ditsch N, Sorokina Y, Moebus V, Muck B, Kuhn W, Bastert G, Werner C, Thomssen C, Wallwiener D, Albert U, Bothmann G, Kreienberg R and Lück HJ: Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: Results of a randomised AGO study. Proc Soc Clin Oncol 16: abstr 133, 2002.
35. Mauriac L, Durand M, Avril A and Dilhuydy JM: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2(5): 347-54, 1991.
36. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangié T, Jouve M, Beuzeboc P, Garcio-Giralt E, Salmon RJ, de la Rochefordière A, Campana F and Pouillart P: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A: 645-652, 1994.
37. Jakesz R for the ABCSG: Comparison of pre- vs. postoperative chemotherapy in breast cancer patients: four-year results of Austrian Breast & Colorectal Cancer Study Group (ABCSG) Trial 7. Proc Am Soc Clin Oncol 20: abstr 125, 2001.
38. von Minckwitz G, Blohmer JU, Raab G, Lohr A, Gerber B, Heinrich G, Eidtmann H, Kaufmann M, Hilfrich J, Jackisch C, Zuna I and Costa SD; German Breast Group: In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16(1): 56-63, 2005.
39. Euler U, Buehner M, Tio J, Dresel V, Rinas N, Schulze W and Tulusan A: Primary systemic chemotherapy (PST) with dose and time intensified epirubicin (E) and cyclophosphamid (C) in locally advanced breast cancer (BC) - an attempt to identify predictive markers. Proc Am Soc Clin Oncol 21: abstr 126, 2002.
40. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L and Hortobagyi GN: Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 3: 379-398, 2004.
41. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Aran BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D and Hortobagyi GN: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676-3685, 2005.
42. Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Höfler H, Jänicke F and Graeff H: Time-varying prognostic impact of tumor biological factors urokinase (uPA), PAI-1, and steroid hormone receptor status in primary breast cancer. Br J Cancer 76(3): 306-311, 1997.
43. Kates R, Schmitt M and Harbeck N: Advanced statistical methods for the definition of new staging models. Recent Results in Cancer Research 162: 101-113, 2003.
44. Cheung KL, Howell A and Robertson JF: Preoperative endocrine therapy for breast cancer. Endocr Relat Cancer 7: 131-141, 2000.
45. Paepke S, Jacobs VR, Paepke D, Euler U, Blohmer JU, Warm M, Ohlinger R, Fischer T, Kiechle M and Harbeck N: Critical appraisal of primary systemic endocrine therapy in receptor-positive postmenopausal breast cancer: an update. Onkologie 29(5): 210-217, 2006.
46. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN and Gonzalez-Angulo AM: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24(7): 1037-1044, 2006.
47. Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U and von Kleist S: Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67: 421-428, 1991.
48. Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, Robertson JF, Blamey RW and Ellis IO: Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71: 146-149, 1995.
49. Brown RW, Allred CD, Clark GM, Osborne CK and Hilsenbeck SG: Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2: 585-592, 1996.
50. Railo M, Lundin J, Haglund C, von Smitten K, von Boguslawsky K and Nordling S: Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol 36: 369-374, 1997.
51. Bonetti A, Zaninelli M, Rodella S, Molino A, Sperotto L, Piubello Q, Bonetti F, Nortilli R, Turazza M and Cetto GL: Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma. Breast Cancer Res Treat 38: 289-297, 1996.
52. Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelenat H and Vielh P: Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77: 292-300, 1996.
53. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I and Coindre JM: Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 74: 1458-1465, 1996.
54. Harbeck N, Kates R and Schmitt M: Clinical relevance of invasion factors uPA and PAI 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncology 20(4): 1000-1009, 2002.
55. Olsson H, Baldetorp B, Ferno M and Perfekt R: Relation between the rate of tumour cell proliferation and latency time in radiation associated breast cancer. BMC Cancer 3: 11, 2003.
56. Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Garcia-Conde J, Zambetti M, Valagussa P and Bonadonna G: First report of the European Cooperative Trial in operable breast cancer (ECTO): Effects of primary systemic therapy (PST) on local-regional disease. Proc Am Soc Clin Oncol 21: abstr 132, 2002.